ECT
31.1.2020 10:32:09 CET | Business Wire | Press release
ECT (European Computer Telecoms AG), Europe’s leading communications software company for the realization of value-added services, announces that the company again achieved record growth in 2019. The company experienced an annual order intake of over 23 million EUR. Although the company’s audited, consolidated annual report has yet be completed, it is already clear that in 2019 ECT exceeded the 20% top-line growth achieved in the previous year, while the bottom line grew by over 30%. In addition, due to the high order backlog at the close of 2019 and maintenance contracts for 2020, ECT already has more than 12 million EUR on its books for this year and anticipates continued record growth.
This landmark development is in line with the Board’s long-term goal of maintaining at least 20% year-to-year revenue growth. As Marshall E. Kavesh, the CEO and cofounder of ECT, explains, “after more than 20 years as a profitable, but midsized market player, we last year took on the ambitious goal of growing ECT from a 20 million Euro to a 100 million Euro company by no later than 2025. With the excellent results of the last two years we have made important steps in this direction. Our continued growth, profitability, customer relationships and innovations are the foundation for the long-term prosperity and independence of our company. This is a commitment we make to all the colleagues in our fantastic ECT team and especially to our much appreciated customers.”
Key highlights for 2019 include:
Expanded Depth and Breadth of Customer Relationships
- The vast majority of the orders were received from first-tier carriers which have been ECT customers for 10 years and longer, attesting to the deep satisfaction of the company’s customer base.
- In addition, the company, whose roots are in Europe, continued to expand its footprint in the Americas with new customer acquisitions and conducted direct sales worldwide.
- With one of Finland’s leading telecommunications operators, DNA, the company closed a three-year contract worth many millions of euros for the provision of, amongst other things, licenses for ECT’s application for Virtual PBX / Unified Communications, a license for the Service Creation Environment of the company’s Telephony Application Server (TAS) as well as the utilization of a Dedicated Agile Programming Squad .
- In indirect sales via its partner Nokia Software, the company took part in tenders worldwide, e.g. closing yet another major multimillion deal.
Major Investments in Cutting-Edge Telecoms Technology
- The company founded a new R&D unit for NFVi architecture, implemented integration with Nokia’s CloudBand Application Manager (CBAM) and plans to continue certification with other major VNF Managers in 2020. Few competitors are capable of offering this important, cost-reducing technology.
- All new solutions are implemented based on ECT’s VNFs with the option of full integration with a third-party VNF Manager, providing Automated Lifecycle Management.
- ECT implemented agile methodology throughout the company starting in January 2019 and also launched a program allowing CSPs to take under contract an ECT Dedicated Agile Programming Squad, enabling them to respond in extremely short cycles to the customizations and enhancements demanded by their major corporate and municipal customers.
- Within the framework of ECT’s Joint Agile Product Development, the company’s Innovation Department successfully launched its cutting-edge application for unified communications and collaboration, ECT Workspace, with selected CSPs.
Rapid Organization Growth
- Although many other telecoms vendors are in retrenchment, ECT is accelerating the growth of its team: In 2019, the number of employees increased by ca. 25% compared to 2018 and is expected to grow by at least another 25% by the end of this year, the majority of the new positions being in R&D.
About ECT (European Computer Telecoms AG):
For more information about ECT, please visit our website: www.ect-telecoms.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom